Expert review of cardiovascular therapy · 2024
Treatment options for hypertrophic obstructive cardiomyopathy: a patient-centric review.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cirillo Chiara, Perillo Andrea, Monda Emanuele, Palmiero Giuseppe, Verrillo Federica, Rubino Marta, Diana Gaetano, Dongiglio Francesca, Caiazza Martina, Cirillo Annapaola, Fusco Adelaide, Fumagalli Carlo, Bossone Eduardo, Russo Maria Giovanna, Calabro Paolo, Limongelli Giuseppe
Аннотация
INTRODUCTION: Hypertrophic cardiomyopathy (HCM) is defined by an increased left ventricular wall thickness not solely explainable by abnormal loading conditions. Estimated prevalence is 1:200-500 with roughly 60% of cases showing a familiar trait. Medical treatment and surgical interventions significantly altered prognosis in HCM. Recently, new therapies have been introduced in clinical practice and a patient-centric approach is key to HCM optimal management. This review aims to summarize the current HCM therapies focusing on the importance of personalized care and delineate therapeutic approaches under investigation.
AREAS COVERED: The review summarizes and critically evaluates the available data on currently available pharmacological and non-pharmacological therapies for HCM. The evidence in support of the use of beta-blockers, non-dihydropyridine calcium channel blockers, disopyramide, and cardiac myosin inhibitors is discussed. Furthermore, data and controversies on sudden death prevention, surgical and non-surgical septal reduction therapies are reported. Finally, future perspectives in HCM management such as new drugs and gene therapies are explored.
EXPERT OPINION: The authors stress the need for a personalized and tailored approach to managing patients with HCM, which is not only based on phenotypes and risk stratification, but also patients' preferences, needs, and beliefs.
AREAS COVERED: The review summarizes and critically evaluates the available data on currently available pharmacological and non-pharmacological therapies for HCM. The evidence in support of the use of beta-blockers, non-dihydropyridine calcium channel blockers, disopyramide, and cardiac myosin inhibitors is discussed. Furthermore, data and controversies on sudden death prevention, surgical and non-surgical septal reduction therapies are reported. Finally, future perspectives in HCM management such as new drugs and gene therapies are explored.
EXPERT OPINION: The authors stress the need for a personalized and tailored approach to managing patients with HCM, which is not only based on phenotypes and risk stratification, but also patients' preferences, needs, and beliefs.